The Momentum and Momentum MIS posterior spinal fixation systems and V-STEADY Bone Cement. Credit: ulrich medical USA / PRNewswire.

Spine technology company ulrich medical USA has received clearance from the US Food and Drug Administration (FDA) for expanded indications of its Momentum and Momentum MIS posterior spinal fixation systems.

This approval allows the systems to be used with G21 V-STEADY Radiopaque Bone Cement, enhancing treatment options for patients with advanced-stage spinal tumours.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

ulrich medical USA Technology vice-president Eric Lucas said: “We are pleased to have received this expanded indication from the FDA.

“The combination of Momentum with V-STEADY offers our surgeon customers a new treatment option to support their most challenging patients.”

The Momentum systems are designed for stabilisation, fixation, and correction of the thoracolumbar and sacroiliac spine.

See Also:

They support various adult degenerative and deformity cases, including occiput to pelvis connections, bone cement augmentation, and revisions for adjacent segment disease in spinal alignment restoration.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

UCSF health orthopaedic spine surgery assistant professor Alekos Theologis said: “I’m excited that I can now use Momentum in conjunction with V-STEADY.

“Momentum has been a valuable treatment option and this enhancement will be beneficial to a segment of my patients.”

In October 2023, ulrich medical USA commercially introduced the Momentum MIS posterior spinal fixation system in the country.

This device was introduced earlier this year and the limited launch phase recently concluded successfully.

Momentum MIS offers a percutaneous solution to ulrich medical USA to meet the demand in the minimally invasive surgery market.

The company, a subsidiary of Germany-based ulrich medical, offers innovative spine technology and expandable corpectomy devices.